Market News · Equity Story

11 November 2024 05:41PM

Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard

DE000A1EWVY8

Press Release // November 11, 2024Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard Dr. Stefan Glombitza has been appointed as CEO for three more years and will lead Formycon through the next phase of the company's development Formycon shares will be admitt...

Formycon AG

Type	Total	Last	Made by	Go to
Corporate Research	17	1^st October 2024	EQS Group AG	Corporate Research
Directors Dealings	4	30^th April 2024	Mikulcik, Dr. Marc	DD
Short Seller (DE)	0	-	-	SSR (DE)
Short Seller (UK)	0	-	-	SSR (UK)

Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard

Corporate News Formycon AG

Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard

Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange

Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D

Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)

FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)

Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases

Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna

Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna

Formycon reports a strong first half-year with multiple milestones achieved

Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences

Formycon AG increases its outlook for the 2024 fiscal year

Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206

Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®

Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA

Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)

FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)

FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)

Formycon reports on the results of the Annual General Meeting

Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda

MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region

MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region

Formycon reports on successful operating business and financial figures for the first quarter of 2024

Formycon invites to the Annual General Meeting on June 12, 2024 in Munich

Formycon hosts conference call on the results of the first quarter 2024

Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance

Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024

Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast

Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year

Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)

Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada

FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region

Gedeon Richter becomes strategic investor of Formycon via equity investment

Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor

Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023

Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference

Formycon announces EMA acceptance of the MAA for FYB203, a biosimilar candidate to Eylea® (Aflibercept)

Health Canada approves FYB201/Ranopto® (Ranibizumab), a biosimilar to Lucentis®

Formycon announces participation in international Investor Conferences in Q1/2024

Formycon and Fresenius Kabi announce File Acceptance for FYB202, a biosimilar candidate to Stelara® (ustekinumab), by the U.S. Food and Drug Administration

Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)

Formycon publishes nine-month results for 2023

Formycon hosts conference call on nine-month figures 2023 and presents at further investor conferences

Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States

Formycon and Fresenius Kabi announce European Medicines Agency Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate

Formycon reports successful first half of 2023

Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA)

Formycon hosts conference call on financial and earnings position for H1 2023

Formycon and Fresenius Kabi secure U.S. License Date for proposed Ustekinumab Biosimilar

Disclaimer:

Newsletter